Mimetas

What Mimetas does

MIMETAS B.V. is a privately held Dutch life-sciences tools company founded in 2013 in Leiden, the Netherlands, with parallel founding in Gaithersburg, Maryland, USA, and a third operating entity in Japan. The company develops organ-on-a-chip tissue and disease models under the OrganoPlate platform, which it positions as the world's first mass-produced, quality-controlled organ-on-chip system using PhaseGuide membrane-free microfluidic technology. Its commercial portfolio spans the OrganoPlate core platform, ready-to-use OrganoReady 3D tissue models (colon, kidney, liver, vasculature), peripheral instruments (OrganoFlow rocker, OrganoTEER barrier-function reader), and the OrganoAccess perfusable vascular bed, covering seven organ models across oncology, immunology, metabolic disease, neurology, and ADME/toxicity applications. The portfolio is supported by 130+ peer-reviewed publications and validated in a regulatory setting through the argenx IND submission.

MIMETAS operates a hybrid business model combining product sales (OrganoPlate platforms, OrganoReady kits, OrganoFlow, OrganoTEER, OrganoAccess) with CRO services delivered through an enterprise field-sales motion targeting pharmaceutical and biotechnology customers. Pricing is quote-based, multi-year, and not publicly disclosed. Revenue streams include one-time product licenses, professional services (CRO and training), and participation in large Dutch and EU-funded consortia (Holomicrobiome Institute, Oncode Accelerator, GRIPonMASH, Project SECRET, EU Animal-Free Innovation). The customer base is concentrated in named top-tier pharma and biotech accounts (Roche, Astellas, Galapagos, argenx), supplemented by academic collaborations (University of Texas Health Center, Dundee), with the company citing 200+ successful projects across all phases of drug discovery and a 4.8/5 customer satisfaction score.

The company is co-led by founders Paul Vulto and Jos Joore as Co-Chief Executive Officers, with Dhaval Patel as Chair of the Board and a management bench spanning CTO (Bas Trietsch), VP Biology (Henriette Lanz), VP BD (Remko van Vught), VP Marketing & Sales (Mieke Doornbos), Japan President (Yoko Ejiri), and US Director (Dwayne Dexter). Strategic positioning has increasingly shifted toward industry-standardization and regulatory-acceptance leadership, evidenced by the 2026 co-founding of IAMPS, the Dutch Innovation Award 2022, and Vulto's 2023 induction as a Fellow of the Netherlands Academy of Engineering.

Name

Mimetas

Legal name

MIMETAS B.V.

Website

https://mimetas.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

101–250 employees

Short description

MIMETAS B.V. develops organ-on-a-chip tissue and disease models on its OrganoPlate platform for pharmaceutical and biotechnology drug discovery. The Netherlands-based company sells platforms, ready-to-use 3D tissue models, peripherals, and CRO services, and is a co-founder of the IAMPS microphysiological systems industry alliance.

Ownership category

akta.pro rank

Product category

Organ-on-Chip Technology

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)

akta.pro secondary industries

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ), Microscopy, Imaging & Flow Cytometry Instruments (HLAGAIAE)

Keywords

• Organ-on-chip technology
• Microfluidic cell culture
• 3D tissue models
• Drug discovery services
• Preclinical drug testing

Headquarters

HQ city

Leiden

HQ country

Netherlands

HQ region

Europe

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Products: Sale of organ-on-a-chip products including OrganoPlate platforms, OrganoReady organoids, OrganoTEER devices, and OrganoFlow rocker devices.
2. CRO Services: Contract research organization services providing drug discovery support across all phases including target validation, compound screening, and toxicity assessment using their organ-on-a-chip models.
3. Training: Training services for customers learning to use organ-on-a-chip technology and platforms.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Core offering

MIMETAS develops and manufactures organ-on-a-chip products, centered on the OrganoPlate microfluidic platform, which enables culturing and screening of miniaturized 3D human tissue and disease models with perfused vasculature. The company also offers ready-to-use organoid products (OrganoReady), peripheral devices (OrganoFlow, OrganoTEER, OrganoAccess), and contract research organization (CRO) services and training for pharmaceutical and biotechnology customers.

Product overview

MIMETAS offers a platform-plus-modules architecture centered on the OrganoPlate® microfluidic platform, complemented by ready-to-use tissue models (OrganoReady®), peripheral devices (OrganoFlow® perfusion rockers, OrganoTEER® measurement device), and the OrganoAccess™ vascular bed system. The portfolio includes specialized organ models (Liver, Gut, Kidney, Blood-Brain Barrier, Lung, Vasculature, Nervous System) across research areas (Oncology, Immunology, Metabolic Disease, Neurology, ADME/Toxicity). The company also provides CRO services and training to support technology adoption.

Differentiator

Problem solved

Functional benefit

Brands

• OrganoPlate: The world's first mass-produced, quality-controlled organ-on-a-chip platform for physiologically relevant cell culture
• OrganoReady
• OrganoTEER
• OrganoFlow
• OrganoAccess

Products and services

• OrganoPlate The flagship microfluidic cell culture platform enabling culturing and screening of miniaturized 3D organs and tissue models with perfusion capabilities, featuring membrane-free PhaseGuide technology.
• OrganoReady Ready-to-use 3D human tissue models including Colon Organoid, Blood Vessel HUVEC, Kidney Organoid, and Liver Organoid for drug discovery and toxicity testing.
• OrganoFlow Gravity-driven rocker device providing continuous, bidirectional perfusion for OrganoPlate platforms, available in S (1-4 plates) and L (up to 16 plates) formats, enabling pump-free operation inside standard incubators.
• OrganoTEER Device for measuring transepithelial electrical resistance (TEER) to assess barrier integrity and function in 3D in vitro tissue barrier models under flow conditions.
• OrganoAccess Perfusable vascular bed for advanced 3D tissue modeling that enables establishment of functional microvascular plexus with unidirectional perfusion without pumps, tubing, or complexity.
• CRO Services Contract research organization services leveraging organ-on-a-chip technology for drug discovery across therapeutic areas including oncology, immunology, metabolic disease, neurology, and ADME/toxicity.
• Training Educational programs and training services for customers learning to use the OrganoPlate platform and organ-on-a-chip technologies.

Quantifiable outcome

• 87% sensitivity in predicting drug-induced liver injury
• +1 more outcomes

Named customers7 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Partnerships

13 partnerships are on record, tiered core, flagship and major.

• IAMPS (Industry Alliance for Microphysiological Systems)coreStrategic or Co-development Partner · 10 February 2026European MPS industry leaders announced the creation of the world's first industry association dedicated to representing microphysiological systems providers. Founding members include Alveolix, BiomimX, Chiron, Dynamic42, InSphero, MIMETAS, NETRI, React4Life, and TissUse, headquartered in Switzerland, Italy, Netherlands, Germany, and France. IAMPS will work to increase regulatory acceptance of MPS data, create data-sharing platforms, and advance device standardization.
• AstellasflagshipStrategic or Co-development Partner · 1 January 2023MIMETAS and Astellas entered into strategic partnership on immuno-oncology, later expanded to include automation and application support. Partnership focuses on using organ-on-a-chip technology for drug discovery in immuno-oncology.
• RocheflagshipStrategic or Co-development PartnerCollaboration to develop human disease models for drug development. MIMETAS achieved important milestones in the partnership. Also collaborated on research regarding how ApoE4 affects brain endothelial function and iron transport.
• Yamaha MotorcoreGTM or Marketing PartnerJoint marketing agreement to advance automated human disease model applications for drug development. Combines MIMETAS organ-on-a-chip technology with Yamaha Motor's automation capabilities.
• GalapagoscoreStrategic or Co-development PartnerCollaboration using high-throughput 3D microvessel-on-a-chip on the OrganoPlate platform to study angiogenesis in context of systemic sclerosis. Published in Scientific Reports.
• argenxcoreStrategic or Co-development PartnerMIMETAS contributed human organ-on-a-chip data to IND application by argenx, demonstrating regulatory acceptance of MPS data in drug development.
• University of Texas Health CentercoreStrategic or Co-development PartnerCollaboration to develop a model system that supports culture of clinically relevant patient-derived xenograft (PDX) cells recapitulating aspects of prostate cancer tumor microenvironment using OrganoPlate technology.
• DundeecoreStrategic or Co-development PartnerCollaboration on placenta model to transform pregnancy healthcare, developing placenta-on-a-chip models suitable for standardized studies.
• Holomicrobiome InstitutemajorStrategic or Co-development PartnerMIMETAS participates in Holomicrobiome Institute backed by €200 million from Dutch cabinet, focusing on microbiome research.
• EU Animal-Free Innovation InitiativemajorStrategic or Co-development PartnerMIMETAS participates in €124.5 million initiative to transition to animal-free innovation, with National Growth Fund reserving 125 million euros for transition to animal-free innovation.
• GRIPonMASHcoreStrategic or Co-development PartnerMIMETAS participates in initiative to improve prevention and care of Metabolic dysfunction-Associated Steatohepatitis (MASH).
• Oncode AcceleratormajorStrategic or Co-development PartnerMIMETAS participates in €325 million Oncode Accelerator initiative to accelerate and improve oncology drug development.
• Project SECRETcoreStrategic or Co-development PartnerEU funded regenerative medicine research project. MIMETAS joins Project SECRET pioneering regenerative medicine research with EU funding.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Lonza: Global contract development and manufacturing organization with significant cell, tissue, and primary-cell-model offerings for pharma. Comparable as a broad incumbent supplying human-relevant biological tools and services to pharma discovery and development.

Direct peers

• Emulate: Direct competitor offering organ-on-a-chip platforms (Emulate Liver-Chip, etc.) and CRO services to pharma. Closest in product category, customer base (top pharma), and business model (products + CRO) to MIMETAS.
• TissUse: Berlin-based developer of multi-organ-chip platforms (MOC) for pharma drug testing and toxicology. Directly comparable as a European organ-on-a-chip vendor offering products and services to pharma/biotech.
• CN Bio: UK-based organ-on-a-chip company offering PhysioMimix platform and contract research for liver, lung, and disease modeling. Directly comparable products-plus-CRO model targeting pharma drug discovery.
• InSphero: Switzerland-based 3D in vitro organoid and microtissue specialist serving pharma with products (Akura plates) and services. Comparable in offering 3D human tissue models and CRO services for ADME/tox and disease modeling.

Emerging players

• React4Life: Italian organ-on-chip startup and IAMPS founding member, offering fluid-dynamic models for pharma toxicology testing. Directly comparable in MPS product category and pharma/biotech customer focus.
• NETRI: French organ-on-chip company (IAMPS founding member) offering microfluidic devices for neuro-oncology and neuroscience applications. Comparable as a European MPS product-and-services vendor to pharma.
• BiomimX: Italian organ-on-chip company and IAMPS founding member, focused on cardiac and multi-organ models. Comparable niche European MPS provider serving pharma R&D.
• Dynamic42: German organ-on-chip company (IAMPS founding member) developing immune and infection models for pharma. Comparable emerging European MPS vendor with overlapping customer segments.
• Alveolix: Swiss lung-on-a-chip specialist and IAMPS co-founder. Comparable as a smaller European MPS vendor serving pharma with organ-on-chip models and disease-modeling services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/mimetas_3d
• YouTubeyoutube.com/c/Mimetas
• LinkedInlinkedin.com/company/mimetas

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds5 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mimetas